Back to Medicines

Irbesartan: Protecting Kidneys in Diabetes

Irbesartan: Protecting Kidneys in Diabetes
Prescription Medicines Editorial 25 July 2025

Irbesartan is an angiotensin II receptor blocker - it blocks the receptor angiotensin II acts on, relaxing blood vessels and lowering blood pressure, without the cough that ACE inhibitors cause. What distinguishes it is the evidence behind one particular use: irbesartan was tested specifically in kidney disease in type 2 diabetes, and it slowed progression by more than blood pressure lowering alone would explain.

Follow the instructions on your label. This guide contains no doses.

The kidney evidence

Two trials established this. One showed irbesartan reduced progression from early protein leakage to established kidney disease. The other showed it reduced progression to kidney failure in people who already had it.

Crucially, the benefit was greater than in comparison groups reaching the same blood pressure by other means - so it is not simply a blood pressure effect.

The mechanism is thought to be a reduction in pressure within the filtering units of the kidney, which reduces protein leakage and the scarring that follows.

ACE inhibitors do the same thing, and either class is used. Irbesartan's advantage is the specific trial data in type 2 diabetes.

Protein in the urine

The measurement that matters here is the urine albumin to creatinine ratio, usually done on an early morning sample as part of annual diabetes review.

A raised ratio is the earliest sign of diabetic kidney damage, and it appears years before blood tests change.

It is also an independent marker of cardiovascular risk - so it matters beyond the kidneys.

Finding it raised is the trigger to start an ACE inhibitor or ARB even if your blood pressure is normal, which surprises people handed a blood pressure tablet without high blood pressure.

Ask what your ACR was and whether it is changing - see monitoring long-term medicines.

What else protects the kidney now

Irbesartan is no longer the whole answer. SGLT2 inhibitors slow kidney disease progression substantially, in people with and without diabetes, and are now standard alongside an ACE inhibitor or ARB.

Finerenone adds further benefit in diabetic kidney disease.

If you have diabetes with protein in your urine and are not on an SGLT2 inhibitor, that is worth asking about - see dapagliflozin and empagliflozin.

Glucose control, blood pressure control and stopping smoking all matter as much as any single drug.

Blood tests are part of the treatment

Kidney function and potassium are checked before starting, one to two weeks after starting or any increase, and periodically thereafter.

A small rise in creatinine after starting is expected and is not a reason to stop - it reflects the intended change in pressure within the kidney. A large rise is different, which is what the test distinguishes.

That point matters here more than usual, because the drug is being taken for the kidneys and a falling eGFR looks alarming out of context.

Irbesartan raises potassium, so potassium supplements and salt substitutes containing potassium chloride need checking first - see potassium chloride.

High potassium is commoner in kidney disease, and it is the main reason these drugs sometimes have to be reduced.

Sick day rules

During illness with vomiting, diarrhoea or fever, an ARB combined with a diuretic and an anti-inflammatory is the recognised route to acute kidney injury - and someone with existing kidney disease has less reserve.

Ask whether you have sick day rules covering it - see sick day rules and medicines that affect your kidneys.

Anti-inflammatory painkillers should generally be avoided altogether in diabetic kidney disease; paracetamol is the safer choice - see paracetamol.

No cough

ARBs do not cause the persistent dry cough that affects a meaningful minority on ACE inhibitors, because they do not prevent bradykinin breakdown.

Switching to an ARB is the standard answer when someone cannot tolerate an ACE inhibitor for that reason.

Angioedema is also less common with ARBs, though not impossible - call 999 for any swelling of the mouth or throat or difficulty breathing.

See lisinopril.

Do not combine with an ACE inhibitor

Taking both raises the risk of kidney injury and high potassium without adding benefit - trials found more harm than good, including specifically in kidney disease.

If a "-pril" and a "-sartan" both appear on your repeat list, query it.

Pregnancy

Irbesartan must not be taken in pregnancy. ARBs can seriously harm a developing baby, particularly the kidneys.

If you could become pregnant this should have been discussed at the outset, and raised again if your plans change.

Do not simply stop - a switch is planned. See labetalol.

Side effects

ARBs are among the better-tolerated blood pressure medicines.

Dizziness, particularly early and after increases. Get up slowly.

Headache, fatigue, musculoskeletal pain and raised potassium.

Irbesartan is taken once daily, with or without food, and is available combined with a thiazide diuretic in a single tablet.

There is nothing to feel

Neither blood pressure treatment nor kidney protection produces any sensation.

The benefit is a slower decline in kidney function over years, and reduced stroke and heart attack risk - and it accrues only while you take it.

If this was useful, Valsartan: Also Half of a Heart Failure Drug is worth reading next, and Medicines collects the rest.